Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05560607 · ClinicalTrials.gov registry record · Phase 1
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT05560607 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 19 participants.
The verdict
NCT05560607, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is a two-part study. In Part A, eligible participants will undergo a baseline diagnostic liver biopsy to determine non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) and fibrosis stage, but will not receive study intervention. In Part B, participants with histologically confirmed NAFLD or non-alcoholic steatohepatitis (NASH) will receive study intervention.
Interventions
- DRUG AZD7503 Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2024-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05560607
The ClinicalTrials.gov registry entry for NCT05560607 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD7503 Intervention is the first listed.
NCT05560607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05560607 about?
NCT05560607 is a clinical study titled "Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease". This is a two-part study. In Part A, eligible participants will undergo a baseline diagnostic liver biopsy to determine non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) and fibrosis stage, but will not receive study intervention. In Part B, participants with histologically confirmed NA...
What is the current status of trial NCT05560607?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2022-08-12. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT05560607?
The interventions under investigation include: AZD7503 Intervention (DRUG).
Who is sponsoring clinical trial NCT05560607?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.